Atorvastatin Therapy for Cardiovascular Risk Reduction

Indications and Dosage

The American College of Cardiology recommends atorvastatin to reduce LDL-C in adults with primary hyperlipidemia, with a goal to reduce LDL-C levels 1
For patients with recent ischemic stroke or TIA without known coronary disease and LDL-C >100 mg/dL, atorvastatin 80 mg daily is recommended to reduce stroke recurrence risk, as suggested by the Stroke journal 2
The International Journal of Stroke recommends atorvastatin 80 mg daily for stroke prevention in patients with recent ischemic stroke or TIA, across all resource settings globally 3

In patients with clinical atherosclerotic cardiovascular disease (ASCVD), atorvastatin 80 mg daily is first-line therapy to achieve LDL-C reduction ≥50% and target LDL-C <70 mg/dL, as recommended by the Journal of the American College of Cardiology 1
For diabetic patients aged 40-75 years without ASCVD, atorvastatin 10-20 mg daily (moderate-intensity) is indicated for primary prevention, with a 37% reduction in major cardiovascular events as seen in the CARDS trial 5
In patients with established ASCVD and diabetes, atorvastatin 80 mg daily is recommended, targeting LDL-C <70 mg/dL 6

For patients requiring >45% LDL-C reduction, atorvastatin 40 mg daily is recommended, and if LDL-C remains >70 mg/dL on maximally tolerated atorvastatin, ezetimibe 10 mg daily can be added for an additional 15-25% LDL-C reduction 1
The American College of Cardiology suggests that high-intensity atorvastatin (40-80 mg) reduces ASCVD events by 37% compared to moderate-intensity therapy 5